Scandinavian ChemoTech AB Class B (8V6) Price & Analysis

0 Followers

8V6 Stock Chart & Stats

€0.39

>-€0.01(-6.14%)

At close: Jan 08 4:00 PM EST

€0.39

>-€0.01(-6.14%)

Day’s Range― - ―

52-Week Range€0.13 - €0.68

Previous CloseN/A

Volume0.00

Average Volume (3M)7.00

Market Cap

€7.45M

Enterprise Value€92.22

Total Cash (Recent Filing)€1.46M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.98

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding23,802,313

10 Day Avg. Volume0

30 Day Avg. Volume7

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)37.86

Price to Sales (P/S)9.82

P/FCF Ratio-28.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€1.72M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained TTM revenue growth of ~265% signals rapid commercial traction for the IQWave/TSE platform. Durable top-line expansion widens the installed base, which can drive recurring consumable and service sales, support scale economies, and improve long-term revenue predictability as adoption continues.

Gross Margin ImprovementA swing to ~53% gross margin reflects material improvement in unit economics for treatments. Positive gross margins provide a foundation for operating leverage: as device sales and procedures scale, higher contribution margins can flow to operating profits if fixed costs and SG&A growth are controlled over the medium term.

Low Financial Leverage & Recurring ModelZero reported debt reduces refinancing and interest-rate risk, giving financial flexibility. Combined with a business model that sells capital equipment plus recurring consumables and services, the company has a structural pathway to build predictable, annuity-like revenue tied to installed devices as clinical adoption grows.

Bears Say

Persistent Net LossesA persistent net margin near -50% indicates operating costs far exceed gross profit. Even with revenue growth, sustained losses erode shareholder equity and require external funding. Without durable cost containment or a clear path to operating profitability, long-term financial sustainability is at risk.

Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow means the business consumes cash to fund operations and growth. Although burn improved versus 2023–24, TTM free cash flow still deteriorated vs 2025, increasing reliance on external financing and raising execution risk for commercialization and regulatory initiatives.

Eroding Equity & Funding PressureMaterial equity erosion over multiple years shrinks the balance-sheet buffer against losses and increases the likelihood of dilution or frequent capital raises. Reduced equity limits strategic flexibility and can impair partner or investor confidence if losses and cash burn aren’t reversed within a reasonable timeframe.

Scandinavian ChemoTech AB Class B News

Is 8V6 a Buy, Before Earnings?

Scandinavian ChemoTech AB Class B (8V6) is scheduled to report 4th quarter earnings on 03/05/2024. Regarding Q4 estimates,...

2y ago

8V6

8V6 FAQ

What was Scandinavian ChemoTech AB Class B’s price range in the past 12 months?

Scandinavian ChemoTech AB Class B lowest stock price was €0.13 and its highest was €0.68 in the past 12 months.

What is Scandinavian ChemoTech AB Class B’s market cap?

Scandinavian ChemoTech AB Class B’s market cap is €7.45M.

When is Scandinavian ChemoTech AB Class B’s upcoming earnings report date?

Scandinavian ChemoTech AB Class B’s upcoming earnings report date is Aug 11, 2026 which is in 5 days.

How were Scandinavian ChemoTech AB Class B’s earnings last quarter?

Scandinavian ChemoTech AB Class B released its earnings results on May 20, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Scandinavian ChemoTech AB Class B overvalued?

According to Wall Street analysts Scandinavian ChemoTech AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scandinavian ChemoTech AB Class B pay dividends?

Scandinavian ChemoTech AB Class B does not currently pay dividends.

What is Scandinavian ChemoTech AB Class B’s EPS estimate?

Scandinavian ChemoTech AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian ChemoTech AB Class B have?

Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding.

What happened to Scandinavian ChemoTech AB Class B’s price movement after its last earnings report?

Scandinavian ChemoTech AB Class B reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.473%.

Which hedge fund is a major shareholder of Scandinavian ChemoTech AB Class B?

Currently, no hedge funds are holding shares in DE:8V6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Scandinavian ChemoTech AB Class B

Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.